An Update on New and Existing Treatments for the Management of Melasma
- PMID: 38896402
- PMCID: PMC11358250
- DOI: 10.1007/s40257-024-00863-2
An Update on New and Existing Treatments for the Management of Melasma
Abstract
Melasma is a chronic, acquired disorder of focal hypermelanosis that carries significant psychosocial impact and is challenging for both the patient and the treating practitioner to manage in the medium to long term. Multiple treatments have been explored, often in combination given the many aetiological factors involved in its pathogenesis. Therapeutic discoveries to treat melasma are a focal topic in the literature and include a range of modalities, with recent developments including updates on visible light photoprotection, non-hydroquinone depigmenting agents, oral tranexamic acid, chemical peels, and laser and energy-based device therapy for melasma. It is increasingly important yet challenging to remain up-to-date on the arsenal of treatments available for melasma to find an efficacious and well-tolerated option for our patients.
© 2024. The Author(s).
Conflict of interest statement
Michelle Rodrigues has provided paid lectures for Cynosure and La Roche Posay, as well as Medical Advisory for SkinCeuticals and L’Oreal Group. Christian Gan has no conflict of interest to declare that may be relevant to the contents of this article.
Similar articles
-
Melasma: A critical analysis of clinical trials investigating treatment modalities published in the past 10 years.J Cosmet Dermatol. 2020 Jun;19(6):1284-1289. doi: 10.1111/jocd.13182. Epub 2019 Oct 11. J Cosmet Dermatol. 2020. PMID: 31603285
-
Treatment of melasma with topical agents, peels and lasers: an evidence-based review.Am J Clin Dermatol. 2013 Oct;14(5):359-76. doi: 10.1007/s40257-013-0038-4. Am J Clin Dermatol. 2013. PMID: 23881551 Review.
-
Melasma Treatment: An Evidence-Based Review.Am J Clin Dermatol. 2020 Apr;21(2):173-225. doi: 10.1007/s40257-019-00488-w. Am J Clin Dermatol. 2020. PMID: 31802394
-
Definition of refractory melasma and its treatment: a review.Lasers Med Sci. 2024 Apr 29;39(1):118. doi: 10.1007/s10103-024-04066-3. Lasers Med Sci. 2024. PMID: 38679674 Review.
-
Melasma. Etiologic and therapeutic considerations.Arch Dermatol. 1995 Dec;131(12):1453-7. doi: 10.1001/archderm.131.12.1453. Arch Dermatol. 1995. PMID: 7492140 Review.
Cited by
-
Comparative Efficacy of Skin-Lightening Formulations in Suppressing Ultraviolet B (UVB)-Induced Arachidonic Acid, Alpha-Melanocyte-Stimulating Hormone (α-MSH), and Melanin Expression: An In Vitro Keratinocyte-Melanocyte Co-culture Study.Cureus. 2025 Feb 12;17(2):e78908. doi: 10.7759/cureus.78908. eCollection 2025 Feb. Cureus. 2025. PMID: 40091954 Free PMC article.
-
Melasma secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS).BMC Pharmacol Toxicol. 2025 Mar 31;26(1):73. doi: 10.1186/s40360-025-00912-4. BMC Pharmacol Toxicol. 2025. PMID: 40165336 Free PMC article.
-
In Vivo Evaluation of Melasma Pathologic Features and Treatment Response by 2-Photon Microscopy.JAMA Dermatol. 2025 Aug 13:e252790. doi: 10.1001/jamadermatol.2025.2790. Online ahead of print. JAMA Dermatol. 2025. PMID: 40802269
-
Clinical Efficacy of Cysteamine Application for Melasma: A Meta-Analysis.J Clin Med. 2024 Dec 9;13(23):7483. doi: 10.3390/jcm13237483. J Clin Med. 2024. PMID: 39685940 Free PMC article. Review.
-
Efficacy and Tolerability of a New Facial 2-Mercaptonicotinoyl Glycine-Containing Depigmenting Serum Versus Hydroquinone 4% over 3-Month Treatment of Facial Melasma.Dermatol Ther (Heidelb). 2025 Sep;15(9):2379-2390. doi: 10.1007/s13555-025-01473-4. Epub 2025 Jun 30. Dermatol Ther (Heidelb). 2025. PMID: 40586974 Free PMC article.
References
-
- Sarkar R, Jagadeesan S, Basavapura Madegowda S, Verma S, Hassan I, Bhat Y, et al. Clinical and epidemiologic features of melasma: a multicentric cross-sectional study from India. Int J Dermatol. 2019;58(11):1305–10. - PubMed
-
- Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149(3):572–7. - PubMed
-
- Syder NC, Elbuluk N. The history of melasma: Its roots and evolution. Dermatol Rev. 2023;4(1):5–11.
-
- Vázquez M, Sánchez JL. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. Cutis. 1983;32(1):92, 5–6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources